Logo image of NP5.DE

NEWRON PHARMACEUTICALS SPA (NP5.DE) Stock Price, Forecast & Analysis

Europe - Frankfurt Stock Exchange - FRA:NP5 - IT0004147952 - Common Stock

25.45 EUR
-0.15 (-0.59%)
Last: 1/20/2026, 7:00:00 PM

NP5.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap507.98M
Revenue(TTM)51.39M
Net Income(TTM)15.84M
Shares19.96M
Float17.19M
52 Week High34.65
52 Week Low6.03
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)1.36
PE18.71
Fwd PEN/A
Earnings (Next)03-24
IPO2006-12-12
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
NP5.DE short term performance overview.The bars show the price performance of NP5.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100 150 200

NP5.DE long term performance overview.The bars show the price performance of NP5.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 200 400 600

The current stock price of NP5.DE is 25.45 EUR. In the past month the price increased by 15.42%. In the past year, price increased by 156.04%.

NEWRON PHARMACEUTICALS SPA / NP5 Daily stock chart

NP5.DE Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to NP5.DE. When comparing the yearly performance of all stocks, NP5.DE is one of the better performing stocks in the market, outperforming 98.51% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NP5.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to NP5.DE. Both the profitability and the financial health of NP5.DE get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NP5.DE Financial Highlights

Over the last trailing twelve months NP5.DE reported a non-GAAP Earnings per Share(EPS) of 1.36. The EPS increased by 231.65% compared to the year before.


Industry RankSector Rank
PM (TTM) 30.83%
ROA 24.79%
ROE 1086.63%
Debt/Equity 25.32
Chartmill High Growth Momentum
EPS Q2Q%99.22%
Sales Q2Q%249.22%
EPS 1Y (TTM)231.65%
Revenue 1Y (TTM)467.41%

NP5.DE Forecast & Estimates

10 analysts have analysed NP5.DE and the average price target is 20.09 EUR. This implies a price decrease of -21.05% is expected in the next year compared to the current price of 25.45.

For the next year, analysts expect an EPS growth of -200.56% and a revenue growth -66.13% for NP5.DE


Analysts
Analysts84
Price Target20.09 (-21.06%)
EPS Next Y-200.56%
Revenue Next Year-66.13%

NP5.DE Ownership

Ownership
Inst Owners11.35%
Ins Owners10.57%
Short Float %N/A
Short RatioN/A

NP5.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1SAN.MI SANOFI 10.38 191.62B
SAN.PA SANOFI 10.32 190.43B
SNW.DE SANOFI 10.27 188.44B
1MRK.MI MERCK KGAA 15.21 56.39B
MRK.DE MERCK KGAA 14.55 53.96B
UCB.BR UCB SA 39.39 49.19B
UNC.DE UCB SA 39.83 49.74B
1BAYN.MI BAYER AG-REG 8.09 42.43B
BAYN.DE BAYER AG-REG 7.99 41.93B
IPN.PA IPSEN 12.93 11.13B
REC.MI RECORDATI INDUSTRIA CHIMICA 23.56 9.71B
TUB.BR FINANCIERE DE TUBIZE 104.81 9.70B

Related stock screener links

About NP5.DE

Company Profile

NP5 logo image Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

Company Info

NEWRON PHARMACEUTICALS SPA

via Antonio Meucci 3

Bresso MILANO IT

Employees: 22

NP5 Company Website

NP5 Investor Relations

Phone: 39026103461

NEWRON PHARMACEUTICALS SPA / NP5.DE FAQ

Can you describe the business of NEWRON PHARMACEUTICALS SPA?

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.


What is the stock price of NEWRON PHARMACEUTICALS SPA today?

The current stock price of NP5.DE is 25.45 EUR. The price decreased by -0.59% in the last trading session.


Does NP5 stock pay dividends?

NP5.DE does not pay a dividend.


What is the ChartMill technical and fundamental rating of NP5 stock?

NP5.DE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


What is the Price/Earnings (PE) ratio of NEWRON PHARMACEUTICALS SPA (NP5.DE)?

The PE ratio for NEWRON PHARMACEUTICALS SPA (NP5.DE) is 18.71. This is based on the reported non-GAAP earnings per share of 1.36 and the current share price of 25.45 EUR.


What is the next earnings date for NP5 stock?

NEWRON PHARMACEUTICALS SPA (NP5.DE) will report earnings on 2026-03-24, after the market close.